Tomoko Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tomoko Yoshida has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Angela Delaney
Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, TN, USA
4 shared publications - Yutaka Yasui
Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital , Memphis, TN
3 shared publications Carmen L Wilson
Department of Epidemiology and Cancer Control, St.Jude Children's Research Hospital , Memphis, TN 38105
2 shared publicationsGregory T Armstrong
Department of Epidemiology and Cancer Control, St. Jude Children’s Research Hospital , Memphis
2 shared publicationsHuiqi Wang
Department of Epidemiology and Cancer Control, St.Jude Children's Research Hospital , Memphis, TN 38105
2 shared publicationsJessica L Baedke
School of Public Health, University of Alberta , Edmonton
2 shared publications
Latest Publications
- Open Access
- 18 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (10) , 2568-2575
Shifting burden of childhood cancer mortality in the United States: progress and persistent inequities
While 5-year survival following childhood cancer rose greatly from ~60% in the mid-1970s to 85% today, inequities persist and conventional survival metrics obscure the true burden and shifting distribution of deaths. To address this, we used Surveillance, Epidemiology, and End Results registries to evaluate excess mortality rates and counts (AER and AEC), new metrics quantifying mortality attributable to childhood cancer, among 47 545 US children diagnosed before age 20 during 1975-2014, with follow-up through 2018. We quantified trends across subgroups and assessed modification by county-level income and rurality. AER declined across groups but at different magnitudes. From 1975-1979 to 2010-2014, declines were 75% in non-Hispanic White (NHW), 62% in non-Hispanic Black, and ~63% in Hispanic and Asian/Pacific Islander children. Among non-Hispanic American Indian/Alaska Native children, AER fell briefly with no clear improvement subsequently. Absolute burden shifted: AEC fell among NHW (8874 in 1990-1994 to 5134 in 2010-2014) but rose among other subgroups (4826 to 5213). By 2010-2014, non-NHW children accounted for more deaths despite >15 000 fewer diagnoses than NHW children. These findings show a shifting national burden: Despite overall survival gains, persistent and sometimes worsening inequities mean deaths are increasingly concentrated among non-NHW subgroups.
- 18 July 2026
- Published by Oxford University Press (OUP) in American Journal of Epidemiology
- Vol. 195 (10) , 2568-2575
Open AccessShifting burden of childhood cancer mortality in the United States: progress and persistent inequities
While 5-year survival following childhood cancer rose greatly from ~60% in the mid-1970s to 85% today, inequities persist and conventional survival metrics obscure the true burden and shifting distribution of deaths. To address this, we used Surveillance, Epidemiology, and End Results registries to evaluate excess mortality rates and counts (AER and AEC), new metrics quantifying mortality attributable to childhood cancer, among 47 545 US children diagnosed before age 20 during 1975-2014, with follow-up through 2018. We quantified trends across subgroups and assessed modification by county-level income and rurality. AER declined across groups but at different magnitudes. From 1975-1979 to 2010-2014, declines were 75% in non-Hispanic White (NHW), 62% in non-Hispanic Black, and ~63% in Hispanic and Asian/Pacific Islander children. Among non-Hispanic American Indian/Alaska Native children, AER fell briefly with no clear improvement subsequently. Absolute burden shifted: AEC fell among NHW (8874 in 1990-1994 to 5134 in 2010-2014) but rose among other subgroups (4826 to 5213). By 2010-2014, non-NHW children accounted for more deaths despite >15 000 fewer diagnoses than NHW children. These findings show a shifting national burden: Despite overall survival gains, persistent and sometimes worsening inequities mean deaths are increasingly concentrated among non-NHW subgroups.
- 25 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , e2018-e2029
Hypothalamic-pituitary deficiency after radiation in childhood cancer survivors is associated with rare variants in TNS2
Context: Radiation to the hypothalamic-pituitary (HP) region (HP-RT) is a strong risk factor for HP deficiency among childhood cancer survivors (survivors). However, there is inter-individual variability in developing HP deficiency after similar HP-RT dose exposures. Objectives: To assess the genetic contribution to developing deficiencies of GH (GHD), LH/FSH (LH/FSHD), thyroid-stimulating hormone deficiency (thyroid-stimulating hormone deficiency [TSHD]), and ACTH (adrenocorticotropic hormone deficiency [ACTHD]) among survivors exposed to HP-RT. Methods: Eligible participants included 5-year survivors exposed to HP-RT (n = 809; median follow-up 31.9 years) from the St. Jude Lifetime Cohort. We assessed the association between rare variants from whole-exome sequencing data (minor allele frequency [MAF] < 0.01, predicted to be pathogenic by functional prediction tools) and HP deficiency rate (total counts/person-year) among 801 survivors by the exact Poisson test. Genome-wide association analysis (GWAS) was conducted among 606 survivors of European ancestry with available whole-genome sequence data, targeting variants with MAF ≥ 0.01. The replication population was 1328 survivors from the Childhood Cancer Survivor Study (CCSS). Results: Carriers of rare variants in TNS2, a ubiquitously expressed protein-coding gene including in brain, had significantly higher rates of HP deficiencies (rate ratio 2.72 [95% CI 1.81-4.09], P = 1.5 × 10−5) compared to non-carriers, which was replicated in the CCSS. This was also observed in individual HP deficiencies: LH/FSHD (3.31 [1.28-7.99]), TSHD (5.29 [2.42-11.34]), and ACTHD (3.97 [1.05-12.31]). There were no statistically significant variants in GWAS. Conclusion: TNS2 may contribute to radiation-induced HP deficiencies. With further validation, screening for TNS2 variants has potential to help identify individuals who would benefit from surveillance and intervention following HP-RT.
- 25 February 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , e2018-e2029
Hypothalamic-pituitary deficiency after radiation in childhood cancer survivors is associated with rare variants in TNS2
Context: Radiation to the hypothalamic-pituitary (HP) region (HP-RT) is a strong risk factor for HP deficiency among childhood cancer survivors (survivors). However, there is inter-individual variability in developing HP deficiency after similar HP-RT dose exposures. Objectives: To assess the genetic contribution to developing deficiencies of GH (GHD), LH/FSH (LH/FSHD), thyroid-stimulating hormone deficiency (thyroid-stimulating hormone deficiency [TSHD]), and ACTH (adrenocorticotropic hormone deficiency [ACTHD]) among survivors exposed to HP-RT. Methods: Eligible participants included 5-year survivors exposed to HP-RT (n = 809; median follow-up 31.9 years) from the St. Jude Lifetime Cohort. We assessed the association between rare variants from whole-exome sequencing data (minor allele frequency [MAF] < 0.01, predicted to be pathogenic by functional prediction tools) and HP deficiency rate (total counts/person-year) among 801 survivors by the exact Poisson test. Genome-wide association analysis (GWAS) was conducted among 606 survivors of European ancestry with available whole-genome sequence data, targeting variants with MAF ≥ 0.01. The replication population was 1328 survivors from the Childhood Cancer Survivor Study (CCSS). Results: Carriers of rare variants in TNS2, a ubiquitously expressed protein-coding gene including in brain, had significantly higher rates of HP deficiencies (rate ratio 2.72 [95% CI 1.81-4.09], P = 1.5 × 10−5) compared to non-carriers, which was replicated in the CCSS. This was also observed in individual HP deficiencies: LH/FSHD (3.31 [1.28-7.99]), TSHD (5.29 [2.42-11.34]), and ACTHD (3.97 [1.05-12.31]). There were no statistically significant variants in GWAS. Conclusion: TNS2 may contribute to radiation-induced HP deficiencies. With further validation, screening for TNS2 variants has potential to help identify individuals who would benefit from surveillance and intervention following HP-RT.
- 8 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3673-e3684
Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors
Context: The consequences of untreated adult growth hormone deficiency (aGHD) among childhood cancer survivors are not well-defined. The lack of evidence and socioeconomic factors may contribute to underutilization of growth hormone therapy (GHT) among survivors with aGHD. Objectives: To examine the association of GHT use with socioeconomic factors and to assess the impact of untreated aGHD in survivors using insulin-like growth factor-1 (IGF1) as a marker of GH action. Methods: 3902 five-year survivors of childhood cancer aged ≥ 18 years were included. The associations between GHT use and socioeconomic factors (health insurance coverage, income, area deprivation index), and associations between IGF1 levels and prevalences of adverse physical, neurocognitive, and psychosocial outcomes were assessed cross-sectionally by multivariable logistic regression adjusting for potential confounders. Results: Among 354 survivors with severe aGHD, 9.0% were on GHT. Socioeconomic disadvantages were independently associated with less use of GHT [e.g., odds ratio (OR) of GHT use 0.27, 95% confidence interval (CI) 0.08–0.84 for annual household income <$40,000 vs. ≥$80,000]. The low IGF1 group (z-score ≤-2) experienced significantly higher prevalences of various adverse outcomes compared to the normal IGF1 group (z-score >0), including various neurocognitive impairment [e.g., verbal reasoning (OR 2.79, 95% CI 1.95–3.98)], diminished health-related quality of life [e.g., physical functioning (1.97, 1.35–2.86)], abnormal glucose metabolism (1.82, 1.21–2.71), and abnormal fat percentage (3.16, 1.98–5.26). Conclusion: Untreated aGHD potentially contributes to multidimensional adverse outcomes and GHT may provide health benefits among survivors, though socioeconomic disadvantage may limit their access to GHT.
- 8 March 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 110 (11) , e3673-e3684
Adult Growth Hormone Deficiency, Replacement Therapy, and Outcomes in Long-Term Childhood Cancer Survivors
Context: The consequences of untreated adult growth hormone deficiency (aGHD) among childhood cancer survivors are not well-defined. The lack of evidence and socioeconomic factors may contribute to underutilization of growth hormone therapy (GHT) among survivors with aGHD. Objectives: To examine the association of GHT use with socioeconomic factors and to assess the impact of untreated aGHD in survivors using insulin-like growth factor-1 (IGF1) as a marker of GH action. Methods: 3902 five-year survivors of childhood cancer aged ≥ 18 years were included. The associations between GHT use and socioeconomic factors (health insurance coverage, income, area deprivation index), and associations between IGF1 levels and prevalences of adverse physical, neurocognitive, and psychosocial outcomes were assessed cross-sectionally by multivariable logistic regression adjusting for potential confounders. Results: Among 354 survivors with severe aGHD, 9.0% were on GHT. Socioeconomic disadvantages were independently associated with less use of GHT [e.g., odds ratio (OR) of GHT use 0.27, 95% confidence interval (CI) 0.08–0.84 for annual household income <$40,000 vs. ≥$80,000]. The low IGF1 group (z-score ≤-2) experienced significantly higher prevalences of various adverse outcomes compared to the normal IGF1 group (z-score >0), including various neurocognitive impairment [e.g., verbal reasoning (OR 2.79, 95% CI 1.95–3.98)], diminished health-related quality of life [e.g., physical functioning (1.97, 1.35–2.86)], abnormal glucose metabolism (1.82, 1.21–2.71), and abnormal fat percentage (3.16, 1.98–5.26). Conclusion: Untreated aGHD potentially contributes to multidimensional adverse outcomes and GHT may provide health benefits among survivors, though socioeconomic disadvantage may limit their access to GHT.
- 2 March 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (3) , 220-233
Hypogonadism and neurocognitive outcomes among childhood cancer survivors
Childhood cancer survivors are at risk for hypogonadism. Impact of hypogonadism on neurocognitive impairment and emotional distress in the non-cancer population has been shown, however, the relationship among childhood cancer survivor population is unknown. We aimed to evaluate the contribution of hypogonadism to neurocognitive impairment and emotional distress among survivors. Cross-sectional study using retrospective cohort. 3628 survivors who completed standard neurocognitive tests (six domains: processing speed, memory, executive function, attention, academics, global cognition) and self-reported emotional distress were included in our study. Participants were stratified by sex and gonadal status. Outcomes were compared between hypogonadal and eugonadal groups by multivariable analysis, adjusting for established predictors, and mediation analyses to determine the direct/indirect effects of hypogonadism on outcomes. The hypogonadal group exhibited higher prevalence of neurocognitive impairment across domains, but no difference in emotional distress. Hypogonadal females exhibited higher relative risk (1.7, 95% confidence interval 1.2–2.5) for impaired visual processing speed, compared to eugonadal females after adjusting for cancer-related variables. In mediation models, hypogonadism had significant direct (P < 0.01) and indirect (from P < 0.01) impact on impairment in visual processing speed among females. Males demonstrated direct (P = 0.03) and indirect (P = 0.04) impact of hypogonadism on motor processing speed. Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.
- 2 March 2024
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 190 (3) , 220-233
Hypogonadism and neurocognitive outcomes among childhood cancer survivors
Childhood cancer survivors are at risk for hypogonadism. Impact of hypogonadism on neurocognitive impairment and emotional distress in the non-cancer population has been shown, however, the relationship among childhood cancer survivor population is unknown. We aimed to evaluate the contribution of hypogonadism to neurocognitive impairment and emotional distress among survivors. Cross-sectional study using retrospective cohort. 3628 survivors who completed standard neurocognitive tests (six domains: processing speed, memory, executive function, attention, academics, global cognition) and self-reported emotional distress were included in our study. Participants were stratified by sex and gonadal status. Outcomes were compared between hypogonadal and eugonadal groups by multivariable analysis, adjusting for established predictors, and mediation analyses to determine the direct/indirect effects of hypogonadism on outcomes. The hypogonadal group exhibited higher prevalence of neurocognitive impairment across domains, but no difference in emotional distress. Hypogonadal females exhibited higher relative risk (1.7, 95% confidence interval 1.2–2.5) for impaired visual processing speed, compared to eugonadal females after adjusting for cancer-related variables. In mediation models, hypogonadism had significant direct (P < 0.01) and indirect (from P < 0.01) impact on impairment in visual processing speed among females. Males demonstrated direct (P = 0.03) and indirect (P = 0.04) impact of hypogonadism on motor processing speed. Processing speed may be the most vulnerable neurocognitive domain associated with hypogonadism in survivors, while other domains were mainly impacted by cancer-related variables. Our findings support the need for further evaluation of the impact of sex hormone replacement therapy on neurocognitive function.
- Open Access
- 1 October 2023
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 11 (5) , qfad057
Variations in gender identity and sexual orientation of university students
Previous studies have shown that a small percentage of people in the general population have atypical gender identity and/or sexual orientation. This study aimed to explore variations in gender identity and sexual orientation in university students and determine genetic factors associated with these variations. Deviations from complete gender congruence and exclusive heterosexual orientation in 736 Japanese university students were quantitatively assessed with self-assessment questionnaires. Next, we conducted genetic tests for 80 participants who showed relatively low gender identity scores and/or atypical sexual orientation. These genetic tests consisted of repeat number analysis of the androgen receptor gene (AR) and a SKAT-O: an optimal unified sequence kernel association test, which is an exome-based rare variant association study. The results of the genetic tests were compared with the Japanese reference data and the results of our 637 control samples. We calculated the gender identity and sexual orientation scores of all participants and analyzed the molecular data of 80 selected participants. The gender identity scores of 736 participants were broadly distributed: only ~15% of natal males and ~5% of natal females had the maximum score that corresponds to complete gender congruence. The sexual orientation scores also varied: ~80% of natal males and ~60% of natal females showed exclusive heterosexual orientation. We found no association between gender characteristics and AR repeat numbers. The SKAT-O showed that rare damaging variants of TDRP and 3 other genes were more common in the 80 participants than in the control group. Our data support the view that gender is a phenotypic continuum rather than a binary trait. This study quantitatively assessed the gender characteristics of a large cohort of university students. Moreover, we conducted systematic screening for genetic factors associated with gender variations. The weaknesses of the study were the limited analytic power of the questionnaires, the relatively small sample for molecular analyses, and incomplete clinical information and relatively advanced ages of the control group. This study revealed significant variations in gender identity and sexual orientation in university students, which may be partly associated with variants in TDRP or other genes.
- 1 October 2023
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 11 (5) , qfad057
Open AccessVariations in gender identity and sexual orientation of university students
Previous studies have shown that a small percentage of people in the general population have atypical gender identity and/or sexual orientation. This study aimed to explore variations in gender identity and sexual orientation in university students and determine genetic factors associated with these variations. Deviations from complete gender congruence and exclusive heterosexual orientation in 736 Japanese university students were quantitatively assessed with self-assessment questionnaires. Next, we conducted genetic tests for 80 participants who showed relatively low gender identity scores and/or atypical sexual orientation. These genetic tests consisted of repeat number analysis of the androgen receptor gene (AR) and a SKAT-O: an optimal unified sequence kernel association test, which is an exome-based rare variant association study. The results of the genetic tests were compared with the Japanese reference data and the results of our 637 control samples. We calculated the gender identity and sexual orientation scores of all participants and analyzed the molecular data of 80 selected participants. The gender identity scores of 736 participants were broadly distributed: only ~15% of natal males and ~5% of natal females had the maximum score that corresponds to complete gender congruence. The sexual orientation scores also varied: ~80% of natal males and ~60% of natal females showed exclusive heterosexual orientation. We found no association between gender characteristics and AR repeat numbers. The SKAT-O showed that rare damaging variants of TDRP and 3 other genes were more common in the 80 participants than in the control group. Our data support the view that gender is a phenotypic continuum rather than a binary trait. This study quantitatively assessed the gender characteristics of a large cohort of university students. Moreover, we conducted systematic screening for genetic factors associated with gender variations. The weaknesses of the study were the limited analytic power of the questionnaires, the relatively small sample for molecular analyses, and incomplete clinical information and relatively advanced ages of the control group. This study revealed significant variations in gender identity and sexual orientation in university students, which may be partly associated with variants in TDRP or other genes.
- 4 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , e892-e900
Impact of Childhood Cancer on Growth
Along with improvements in cancer treatment over time, the number of childhood cancer survivors has been growing. Survivors are at risk for serious medical complications, and growth impairment is among the most common. There are multiple factors that may cause impaired growth among survivors. In this article, we review the impact of cancer on growth in children and adolescents. We first provide an overview of growth disturbance among childhood cancer patients and survivors due to nonhormonal causes, including a recent understanding of the effect of targeted cancer therapies (eg, tyrosine kinase inhibitors and immune checkpoint inhibitors) on growth. Then we describe the hormonal causes of growth impairment among survivors, focusing on growth hormone deficiency, including the prevalence, risk factors, and treatment. Lastly, we briefly summarize overgrowth and tall stature in childhood cancer. It is critical to assess the linear growth of children and adolescents, especially in cancer survivors who are at risk for growth disturbance, since growth is an important measure of their health.
- 4 August 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , e892-e900
Impact of Childhood Cancer on Growth
Along with improvements in cancer treatment over time, the number of childhood cancer survivors has been growing. Survivors are at risk for serious medical complications, and growth impairment is among the most common. There are multiple factors that may cause impaired growth among survivors. In this article, we review the impact of cancer on growth in children and adolescents. We first provide an overview of growth disturbance among childhood cancer patients and survivors due to nonhormonal causes, including a recent understanding of the effect of targeted cancer therapies (eg, tyrosine kinase inhibitors and immune checkpoint inhibitors) on growth. Then we describe the hormonal causes of growth impairment among survivors, focusing on growth hormone deficiency, including the prevalence, risk factors, and treatment. Lastly, we briefly summarize overgrowth and tall stature in childhood cancer. It is critical to assess the linear growth of children and adolescents, especially in cancer survivors who are at risk for growth disturbance, since growth is an important measure of their health.
- Open Access
- 5 April 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Association of inadequate energy intake on admission with activities of daily living at discharge in patients undergoing unplanned hemodialysis initiation: a retrospective case-series study
- 5 April 2022
- Published by Springer Nature in Renal Replacement Therapy
- Vol. 8 (1) , 1-8
Open AccessAssociation of inadequate energy intake on admission with activities of daily living at discharge in patients undergoing unplanned hemodialysis initiation: a retrospective case-series study
- Open Access
- 8 February 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Massive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer
Background: Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy and immunohistochemical analysis, this technique is not yet considered foolproof for predicting a favorable outcome of PD-1 antibody therapy. We aimed to predict the efficacy of nivolumab based on a comprehensive analysis of RNA expression at the gene level in advanced NSCLC.Methods: This was a retrospective study on patients with NSCLC who were administered nivolumab at the Kansai Medical University Hospital. To identify genes associated with response to anti-PD-1 antibodies, we grouped patients into responders (complete and partial response) and non-responders (stable and progressive disease) to nivolumab therapy. Significant genes were then identified for these groups using Welch’s t-test.Results: Among 42 analyzed cases (20 adenocarcinomas and 22 squamous cell carcinomas), enhanced expression ofMAGE-A4,BBC3,andOTOAgenes was observed in responders with adenocarcinoma, and enhanced expression ofDAB2,HLA-DPB,1andCDH2genes was observed in responders with squamous cell carcinoma.Conclusions: This study predicted the efficacy of nivolumab based on a comprehensive analysis of mRNA expression at the gene level in advanced NSCLC. We also revealed different gene expression patterns as predictors of the effectiveness of anti PD-1 antibody therapy in adenocarcinoma and squamous cell carcinoma.
- 8 February 2022
- Published by Springer Nature in BMC Cancer
- Vol. 22 (1) , 1-10
Open AccessMassive digital gene expression analysis reveals different predictive profiles for immune checkpoint inhibitor therapy between adenocarcinoma and squamous cell carcinoma of advanced lung cancer
Background: Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy and immunohistochemical analysis, this technique is not yet considered foolproof for predicting a favorable outcome of PD-1 antibody therapy. We aimed to predict the efficacy of nivolumab based on a comprehensive analysis of RNA expression at the gene level in advanced NSCLC.Methods: This was a retrospective study on patients with NSCLC who were administered nivolumab at the Kansai Medical University Hospital. To identify genes associated with response to anti-PD-1 antibodies, we grouped patients into responders (complete and partial response) and non-responders (stable and progressive disease) to nivolumab therapy. Significant genes were then identified for these groups using Welch’s t-test.Results: Among 42 analyzed cases (20 adenocarcinomas and 22 squamous cell carcinomas), enhanced expression ofMAGE-A4,BBC3,andOTOAgenes was observed in responders with adenocarcinoma, and enhanced expression ofDAB2,HLA-DPB,1andCDH2genes was observed in responders with squamous cell carcinoma.Conclusions: This study predicted the efficacy of nivolumab based on a comprehensive analysis of mRNA expression at the gene level in advanced NSCLC. We also revealed different gene expression patterns as predictors of the effectiveness of anti PD-1 antibody therapy in adenocarcinoma and squamous cell carcinoma.
- 1 November 2021
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 185 (5) , K7-K11
Quantification of androgens and their precursors in full-term human placenta
Introduction: The two major androgens in humans are testosterone (T) and dihydrotestosterone (DHT). DHT is produced via the classical, backdoor, and alternative steroidogenic pathways. In addition, recent studies have identified C11-oxy C19 steroids as novel human androgens. Although the placenta is known to be involved in steroid metabolism, androgen levels in full-term placentas have poorly been investigated. Subjects and methods: Ten placentas of healthy full-term neonates (five males and five females) were examined. We quantified progesterone, androstenedione (A4), T, allopregnanolone, androsterone, and estradiol, as well as four C11-oxy androgens (11β-hydroxyandrostenedione, 11β-hydroxytestosterone, 11-ketoandrostenedione (11KA4), and 11-ketotestosterone (11KT)), using liquid chromatography-tandem mass spectrometry. Results: In all samples, levels of the ten steroids were above the detection limit. Progesterone was by far most abundant, while levels of T and androsterone were relatively low. Levels of 11KT and 11KA4 were higher than those of T and A4, respectively. There were no differences in steroid levels between male and female samples. Discussion: This study demonstrates that full-term placentas contain several steroids in the classical, backdoor, and alternative pathways. Placentas are likely to function as the supplier of progesterone to other steroidogenic tissues. More importantly, we found that placentas comprise relatively large amounts of 11KA4 and 11KT, which may be produced through steroid transfer from the adrenal gland or from the maternal circulation. These results indicate that the placenta participates in a feto-maternal multi-organ network for androgen biosynthesis.
- 1 November 2021
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 185 (5) , K7-K11
Quantification of androgens and their precursors in full-term human placenta
Introduction: The two major androgens in humans are testosterone (T) and dihydrotestosterone (DHT). DHT is produced via the classical, backdoor, and alternative steroidogenic pathways. In addition, recent studies have identified C11-oxy C19 steroids as novel human androgens. Although the placenta is known to be involved in steroid metabolism, androgen levels in full-term placentas have poorly been investigated. Subjects and methods: Ten placentas of healthy full-term neonates (five males and five females) were examined. We quantified progesterone, androstenedione (A4), T, allopregnanolone, androsterone, and estradiol, as well as four C11-oxy androgens (11β-hydroxyandrostenedione, 11β-hydroxytestosterone, 11-ketoandrostenedione (11KA4), and 11-ketotestosterone (11KT)), using liquid chromatography-tandem mass spectrometry. Results: In all samples, levels of the ten steroids were above the detection limit. Progesterone was by far most abundant, while levels of T and androsterone were relatively low. Levels of 11KT and 11KA4 were higher than those of T and A4, respectively. There were no differences in steroid levels between male and female samples. Discussion: This study demonstrates that full-term placentas contain several steroids in the classical, backdoor, and alternative pathways. Placentas are likely to function as the supplier of progesterone to other steroidogenic tissues. More importantly, we found that placentas comprise relatively large amounts of 11KA4 and 11KT, which may be produced through steroid transfer from the adrenal gland or from the maternal circulation. These results indicate that the placenta participates in a feto-maternal multi-organ network for androgen biosynthesis.
- Open Access
- 23 February 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (8) , 3540-3545
Synergistic roles of the proteasome and autophagy for mitochondrial maintenance and chronological lifespan in fission yeast
Regulations of proliferation and quiescence in response to nutritional cues are important for medicine and basic biology. The fission yeast Schizosaccharomyces pombe serves as a model, owing to the shift of proliferating cells to the metabolically active quiescence (designate G0 phase hereafter) by responding to low nitrogen source. S. pombe G0 phase cells keep alive for months without growth and division. Nitrogen replenishment reinstates vegetative proliferation phase (designate VEG). Some 40 genes required for G0 maintenance were identified, but many more remain to be identified. We here show, using mutants, that the proteasome is required for maintaining G0 quiescence. Functional outcomes of proteasome in G0 and VEG phases appear to be distinct. Upon proteasome dysfunction, a number of antioxidant proteins and compounds responsive to ROS (reactive oxygen species) are produced. In addition, autophagy-mediated destruction of mitochondria occurs, which suppresses the loss of viability by eliminating ROS-generating mitochondria. These defensive responses are found in G0 but not in VEG, suggesting that the main function of proteasome in G0 phase homeostasis is to minimize ROS. Proteasome and autophagy are thus collaborative to support the lifespan of S. pombe G0 phase.
- 23 February 2010
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 107 (8) , 3540-3545
Open AccessSynergistic roles of the proteasome and autophagy for mitochondrial maintenance and chronological lifespan in fission yeast
Regulations of proliferation and quiescence in response to nutritional cues are important for medicine and basic biology. The fission yeast Schizosaccharomyces pombe serves as a model, owing to the shift of proliferating cells to the metabolically active quiescence (designate G0 phase hereafter) by responding to low nitrogen source. S. pombe G0 phase cells keep alive for months without growth and division. Nitrogen replenishment reinstates vegetative proliferation phase (designate VEG). Some 40 genes required for G0 maintenance were identified, but many more remain to be identified. We here show, using mutants, that the proteasome is required for maintaining G0 quiescence. Functional outcomes of proteasome in G0 and VEG phases appear to be distinct. Upon proteasome dysfunction, a number of antioxidant proteins and compounds responsive to ROS (reactive oxygen species) are produced. In addition, autophagy-mediated destruction of mitochondria occurs, which suppresses the loss of viability by eliminating ROS-generating mitochondria. These defensive responses are found in G0 but not in VEG, suggesting that the main function of proteasome in G0 phase homeostasis is to minimize ROS. Proteasome and autophagy are thus collaborative to support the lifespan of S. pombe G0 phase.